This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by TAYLOR, H. C. Articles by ANTON, A. H. Search for Related Content PubMed PubMed Citation Articles by TAYLOR, H. C. Articles by ANTON, A. H.

Clonidine Suppression Test for Pheochromocytoma: Examples of Misleading Results^*

Division of Endocrinology, Lutheran Medical Center
Departments of Anesthesiology and Pharmacology
Case Western Reserve University, School of Medicine Cleveland, Ohio 44113;
Endocrine Sciences Tarzana, California 91356

Address requests for reprints to: Harris C. Taylor, M.D., 2609 Franklin Boulevard, Cleveland, Ohio 44113.

Baseline plasma norepinephrine (NE) and epinephrine (E) levels over 2000 pg/ml or failure to suppress to less than 500 pg/ml after oral clonidine have been considered diagnostic of the presence of a pheochromocytoma. We found a false negative clonidine suppression test in a patient with an asymptomatic ACTH-secreting pheochromocytoma who had minimally increased resting plasma NE and E values of 669 and 419 pg/ml, respectively. Clonidine suppression caused decreases at 2 and 3 h to 372 and 408 pg/ml, respectively. A positive test was found in a patient with repeatedly elevated baseline plasma NE and E concentrations; the two highest results were 2501 and 3022 pg/ml. Clonidine administration on five occasions failed to decrease plasma NE and E levels to less than 500 pg/ml. However, no pheochromocytoma was found by selective venous catheterization, two laparotomies, and, ultimately, postmortem examination. Diffuse infiltration of lymphoplasmacytic cells throughout sympathetic ganglia and adrenal medulla raise the possibility of a diffuse autoimmune disorder, resulting in excessive catecholamine production. These examples suggest that the clonidine suppression test does not always indicate the presence or absence of a pheochromocytoma.

^* Presented at the 67th Annual Meeting of The Endocrine Society, June 20,1985, Baltimore, MD.

Received June 24, 1985.

This article has been cited by other articles:

				K. L. Brain, J. Kay, and B. Shine Measurement of Urinary Metanephrines to Screen for Pheochromocytoma in an Unselected Hospital Referral Population Clin. Chem., November 1, 2006; 52(11): 2060 - 2064. [Abstract] [Full Text] [PDF]

				G. Eisenhofer, D. S. Goldstein, M. M. Walther, P. Friberg, J. W. M. Lenders, H. R. Keiser, and K. Pacak Biochemical Diagnosis of Pheochromocytoma: How to Distinguish True- from False-Positive Test Results J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2656 - 2666. [Abstract] [Full Text] [PDF]

				R. J. Sjoberg, K. J. Simcic, and G. S. Kidd The Clonidine Suppression Test for Pheochromocytoma: A Review of Its Utility and Pitfalls Arch Intern Med, June 1, 1992; 152(6): 1193 - 1197. [Abstract] [PDF]

				W. J. Elliott, M. B. Murphy, F. H. Straus II, and J. Jarabak Improved Safety of Glucagon Testing for Pheochromocytoma by Prior {alpha}-Receptor Blockade: A Controlled Trial in a Patient With a Mixed Ganglioneuroma/Pheochromocytoma Arch Intern Med, January 1, 1989; 149(1): 214 - 216. [Abstract] [PDF]